CERTARA INC

Certara CFO Resigns, 2026 Guidance Stays Steady, Simulations Plus Acquisition Boosts Valuation

Certara Inc. keeps 2026 guidance steady after CFO exit, boosts valuation with Simulations Plus deal—capitalizing on a $9.24 B biosimulation market by 2031.

CERTARA INC
Health Care
Health Care Equipment & Services
AI generated

17/06/2026, 22:59

2 minutes to read

Certara Inc. Faces Analyst Split & Barclays Downgrade Amid Drug‑Discovery Tech Potential

Certara Inc. faces analyst split and a Barclays downgrade, but its biosimulation platform could boost drug‑development speed—watch for revenue wins and partnerships.

CERTARA INC
Health Care
Health Care Equipment & Services
AI generated

07/03/2026, 18:18

3 minutes to read